Tonix Pharmaceuticals Holding TNXP
NASDAQ TNXP
$9.68 +0.03 (+0.31%)
As of: Sep 30, 2026 · 10:24 AM EDT

Tonix Pharmaceuticals Holding (TNXP) Debt Ratio (2010 - 2024)

Updated

Tonix Pharmaceuticals Holding's (TNXP) Debt Ratio stood at 0.05 in Q4 2024, down 20.3% from 0.06 a year earlier and down 45.4% from the prior quarter.

Analysis

Tonix Pharmaceuticals Holding (TNXP) Debt Ratio (2010 - 2024) Analysis & Trends

Starting with Q4 2010, Tonix Pharmaceuticals Holding's Debt Ratio history includes 13 quarters.

  • Across earlier years, Debt Ratio came in at 0.06 in FY2023.
  • The Q4 2024 figure is the lowest quarterly Debt Ratio since Q2 2014.
  • Per Business Quant, the preceding three quarters came in at 0.08 (Q3 2024), 0.12 (Q2 2024) and 0.07 (Q1 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 0.24
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 0.52
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 0.42
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn 0.31
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 0.00
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 0.60
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 0.53
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 0.31
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Tonix Pharmaceuticals Holding 166.24 Mn 166.24 Mn 12.84 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 0.05
Sep 30, 2024 0.08
Jun 30, 2024 0.12
Mar 31, 2024 0.07
Dec 31, 2023 0.06
Jun 30, 2014 0.01
Mar 31, 2014 0.01
Dec 31, 2013 0.03
Sep 30, 2013 0.04
Dec 31, 2011 0.35
Sep 30, 2011 48.78
Jun 30, 2011 13.39
Dec 31, 2010 0.05
API Access

Tonix Pharmaceuticals Holding Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=TNXP&period=max&api_key=YOUR_API_KEY